Dyne Therapeutics, Inc., a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock at a public offering price of $31.00 per share.
